REGENXBIO Inc. Cash and Restricted Cash
REGENXBIO Inc. (RGNX) had Cash and Restricted Cash of $38.52 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $38.52M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $17.26M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $36.50M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $60.83M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $38.52M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $17.26M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $36.50M 10-K · filed 2026-03-05 |
| 2025-09-30 | $60.83M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $81.59M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $132.13M 10-Q · filed 2026-05-14 |
| 2024-12-31 | $59.56M 10-K · filed 2026-03-05 |
| 2024-09-30 | $58.65M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $59.80M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $115.00M 10-Q · filed 2025-05-12 |
| 2023-12-31 | $36.55M 10-K · filed 2025-03-13 |
| 2023-09-30 | $55.30M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $70.86M 10-Q · filed 2024-08-01 |
| 2023-03-31 | $72.12M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $98.98M 10-K · filed 2025-03-13 |
| 2022-09-30 | $120.57M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $123.40M 10-Q · filed 2023-08-02 |
| 2022-03-31 | $193.90M 10-Q · filed 2023-05-03 |
| 2021-12-31 | $347.24M 10-K · filed 2024-02-27 |
| 2021-09-30 | $229.72M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $258.40M 10-Q · filed 2022-08-03 |
| 2021-03-31 | $292.81M 10-Q · filed 2022-05-04 |
| 2020-12-31 | $339.76M 10-K · filed 2023-02-28 |
| 2020-09-30 | $94.55M 10-Q · filed 2021-11-02 |
| 2020-06-30 | $95.55M 10-Q · filed 2021-08-09 |
| 2020-03-31 | $70.74M 10-Q · filed 2021-05-05 |
| 2019-12-31 | $70.84M 10-K · filed 2022-03-01 |
| 2019-09-30 | $80.65M 10-Q · filed 2020-11-04 |
| 2019-06-30 | $56.20M 10-Q · filed 2020-08-06 |
| 2019-03-31 | $56.91M 10-Q · filed 2020-05-07 |
| 2018-12-31 | $76.61M 10-K · filed 2021-03-01 |
| 2018-09-30 | $142.65M 10-Q · filed 2019-11-05 |
| 2018-06-30 | $107.11M 10-Q · filed 2019-08-07 |
| 2018-03-31 | $72.09M 10-Q · filed 2019-05-07 |
| 2017-12-31 | $46.88M 10-K · filed 2020-02-26 |
| 2017-09-30 | $60.11M 10-Q · filed 2018-11-07 |
| 2017-06-30 | $57.87M 10-Q · filed 2018-08-08 |
| 2017-03-31 | $82.27M 10-Q · filed 2018-05-08 |
| 2016-12-31 | $25.07M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |